FOR OFFICE USE ONLY: IRB Protocol # Application Received: Routed: Training Complete:



Committee for Research Involving Human Subjects (IRB) Application for Approval Form

Please send your completed application to comply@k-state.edu

Last Revised: 1/18/2019 **ADMINISTRATIVE INFORMATION:** Title of Project/Course: Tip: Decide what you want to call your research study. Type of Application: New / Renewal Revision (to a pending new application) (check one box) Modification to an existing approved application #: on approval letter Principal Investigator Details: (must be a KSU faculty member): Name: Degree/Title: Department: Campus Phone: Campus Address: E-mail: Fax# Responsible Graduate Student: (Person to contact for questions/problems with the form): Name: Campus Phone: E-mail: Does this project involve any collaborators not part of the faculty/staff at KSU? (projects with non-KSU collaborators may require additional coordination and approvals): □ No □ Yes Project Classification (Is this project part of one of the following?): Thesis Dissertation Faculty Research Other: Note: Class Projects should use the short form application for class projects. Copy will be submitted to comply@ksu.edu with this application Copy of the Consent Form: Consent form not used **Funding Source:** Federal State Internal Other Funding Agency: Please give name of Funding Agency. (You will also need to provide a copy of the sponsor's grant application or contract as submitted to the funding agency. Submit documents to comply@ksu.edu with your application.) Based upon criteria found in 45 CFR 46 – and the overview of projects that may qualify for exemption explained at http://www.hhs.gov/ohrp/ policy/checklists/decisioncharts.html, I believe that my project using human subjects should be determined by the IRB to be exempt from IRB review: No Yes (If yes, please provide the category of "Exemption" in the space below) Exempt Projects: 45 CFR 46 identifies six categories of research involving human subjects that may be exempt from IRB review. The categories for exemption are listed here: http://www.hhs.gov/ohrp/policy/checklists/decisioncharts.html#c2 If you believe that your project qualifies for exemption, please indicate which exemption category applies (1-6). Please remember that only the IRB can make the final determination whether a project is exempt from IRB review, or not. **Exemption Category:**

Is this If you a in the f	are reques	ication of an approved proting a modification or a change block. Additionally, please hi	otocol? No Yes If yes, please comply with the following: e to an IRB approved protocol, please provide a concise description of all of the changes that you are proposing ghlight or bold the proposed changes in the body of the protocol where appropriate, so that it is clearly re the proposed changes are. This will greatly help the committee and facilitate the review.						
(e.g., to Start vorigination the top	use a new with your al applica of this ptions as n	data collection method, co original application conten- ation used an older form, you page and immediately above eeded to reflect the changes	reived approval of an IRB application for your study, and you want to make some modifications llect data from a new audience), you should submit a modification rather than a new application. It. [Note. Make sure you are using the most current version of the IRB application form; if your usually usually usually usually need to transfer the content over to the new form.] Mark the application as a modification at the Describe the changes/additions to your study here. Then, throughout the application make updates to your study. Be sure to highlight additions so reviewers can easily see what is new. For example, he new/changed text by holding down the Control button and the B, U, or I keys, respectively.						
I.		-TECHNICAL SYNOP and be easily understood b	SIS (Please provide a brief narrative description of proposal. This should typically be less than 75 y nonscientists):						
	box in	the application that specifi	would to a family member, friend, or neighbor. Keep it simple and brief. This is the one response es a word limit, so try to limit your response to 75 words, as instructed. To check the word count, osoft Word document and use the Word Count function on the Review tab.						
II.	BAC	KGROUND (concise narr	ative review of the literature and basis for the study):						
	article inforn	e. If you've already developed nation from your grant or the	is you would in the literature review section of a grant proposal, thesis, dissertation, or journal and a literature review related to your study, you won't need to start from scratch (e.g., paste esis proposal). The instructions request you keep it concise, so only include as much information in the need for your study. This is not expected to be long (it might be half a page or so).						
III.	PROJECT/STUDY DESCRIPTION (Please provide a concise narrative description of the proposed activity in terms that will allow the IRB or other interested parties to clearly understand what it is that you propose to do that involves human subjects. This description must be in enough detail so that IRB members can make an informed decision about the proposal).								
	target e.g., v specif interv	audience(s) - e.g., universit veb-based survey, face-to-fa ic event, curriculum, progra	r study (e.g., who, what, where, when, and how). From whom will you collect data (specify the try students, K-12 teachers/administrators)? How will you collect the data (specify the method(s) - ace interviews)? What will be the focus/topic of the data collection (e.g., gaining feedback on a tam)? When will you collect the data (e.g., how many times - once, before and after an allect data (e.g., virtually, or onsite at specific locations). Keep it concise; you will provide application.						
IV.		ECTIVE v state the objective of the rese	arch – what you hope to learn from the study).						
	-		ypotheses your study is seeking to answer/test.						
v.	DESI A.	DESIGN AND PROCEDURES (succinctly outline formal plan for study) A. List all sites where this research will be conducted:							
		Tip: List specific location	ons where your data will be collected (e.g., names of universities, cities, schools). If data collections o-based surveys, telephone/Zoom interviews), indicate that as well.						
	B.	Variables to be studied:	Tip: Describe the types of information you will be asking from participants. For example, will you be asking participants' feedback related to specific programs or curriculum (strengths, areas for improvement, impacts)? Will you be collecting their responses related to specific research						

IRB Application

Page 2

IRB Application Page 3

constructs? Make sure the instruments (e.g., surveys, interview questions) submitted with your application focus on the variables listed here.

Data collection methods: (surveys, instruments, etc - copies must submitted to comply@k-state.edu).

Tip: Describe the methods you will use to collect data from your participants. For example, will you collect data through surveys (hard copy, web-based), interviews (face-to-face, telephone, video), focus groups (face-to-face, video), observation, or others? Specify if you will use different methods with different audiences (e.g., interviews with school administrators, web-based surveys with teachers).

D. List any factors that might lead to a subject dropping out or withdrawing from a study. These might include, but are not limited to emotional or physical stress, pain, inconvenience, etc.

Tip: It is okay to say "None". At OEIE, we typically say "Participants may not participate or may withdraw from data collections if they are too busy."

E. List all biological samples taken: (if any)

Tip: If you are not taking biological samples, say "Not Applicable."

Describe storage and disposition of biological samples: (How long will samples be kept, will samples be used for other purposes, how will samples be destroyed)

Tip: If you are not taking biological samples, say "Not Applicable."

Will whole genome sequencing be used:

No

Yes

F. Debriefing procedures for participants:

Tip: Describe what you plan to say to participants at the conclusion of the data collection (e.g., in a closing message on a survey, or verbally as you end an interview). Explain next steps for the study (what you will be doing with the data) and the extent to which their data will be kept confidential. Also provide contact information for the study researcher and the K-State Research Compliance Office, in case participants have follow-up questions.

VI. RESEARCH SUBJECTS:

A. Source:

Tip: List all of your target audience(s). From whom will you be collecting data (e.g., K-12 teachers, K-12 students, university students, university faculty/staff)?

B. Number: (provide a brief rationale for your sample size)

Tip: It is okay to provide an estimate or approximate number. If you have multiple target audiences listed as Sources in the box above (e.g., K-12 teachers and K-12 students), provide an estimate for each audience. For example, "Approximately 10 K-12 teachers and 200 K-12 students."

C. Inclusion criteria: (List any unique qualifiers desirable for research subject participation)

Tip: Explain how you will select your sample of participants. Will you target individuals attending an event or participating in a specific program/course?

D. Exclusion criteria: (list any unique disqualifiers for research subject participation)

Tip: Explain how you will limit your sample of participants. For example, it may be the opposite of your inclusion criteria (e.g., anyone who does not attend the event, or participate in the program/course, will not be asked to participate).

E. Recruitment procedures:

How will subjects be identified?

Tip: Describe how you will determine your list of participants. For example, will a course instructor provide a list of students in the course, or will an event organizer provide a list of people who attended the event? Will a sign-up sheet be posted where individuals can sign up to participate (participants identify themselves)?

How will subjects be recruited (advertisement, associates, etc.)?

Tip: Describe how potential participants will become aware of the opportunity to participate in the study. For example, will
you post a flyer or sign-up sheet? Will the course instructor inform their students of the study? Will you contact the
participants directly by email? Or a combination of methods?
YY 111 11 11 12

How will subjects be enrolled?

Tip: Describe how individuals become participants in your study. For example, do they respond to your email with interest in participating? Do they enter their name on a sign-up sheet? Do they show up at the identified data collection time/location? Do they respond to a survey?

Describe any follow-up recruitment procedures: (reminder emails, mailings, etc.)

Tip: Describe what you will do following the initial recruitment efforts you described above. For example, will you send email reminders periodically to individuals who have not yet responded to your initial email invitation? Will you ask a course instructor or other contact to reach out to potential participants to remind them of the study and encourage their participation? Will you attempt to contact individuals by telephone?

VII. <u>RISK - PROTECTION - BENEFITS</u>: The answers for the three questions below are central to human subjects research. You must demonstrate a reasonable balance between anticipated risks to research participants, protection strategies, and anticipated benefits to participants or others.

A.	Ris	k for Subjects: (check all that apply)
		Exposure to infectious diseases
		Use of confidential records
		Exposure to radiation
		Manipulation of psychological or social variables such as sensory deprivation, social isolation, psychological stressors
		Examining for personal or sensitive information in surveys or interviews
		Presentation of materials which subjects might consider sensitive, offensive, threatening, or degrading
		Invasion of privacy of subject or family
		Social or economic risk
		Risk associated with exercise or physical exertion
		Legal risk
		Review of medical records
		Review of criminal records
		HIV/AIDS or other STD's
		Employment/occupational risk
		Others – Please explain below (Indirect risks, risk to individuals who are not the primary subjects):

B. Minimizing Risk: (Describe specific measures used to minimize or protect subjects from anticipated risks.)

Tip: Considering risks you identified above, describe how you will attempt to protect participants from those risks. Describe how participants' data will be kept confidential. For example, will results be reported in aggregate, with no participants identified in reports or presentations of findings? Will you not report back to course instructors or program coordinators who has vs. has not participated?

C. Benefits: (Describe any reasonably expected benefits for research participants, a class of participants, or to society as a whole.)

Tip: Describe what are you hoping to learn, and whom that knowledge will benefit. For example, will your study result in improved curriculum or instruction for the preparation of future teachers, and improved learning outcomes for students? Will results of your study possibly help to secure future funding?

Answer the following questions about the informed consent procedures.

Yes No A. Are you using a written informed consent form? If "yes," include a copy with this application. If "no" see B.

IRB Application			Page 6
Yes	☐ No	В.	In accordance with guidance in 45 CFR 46, I am requesting a waiver or alteration of informed consent elements (see section VIII above). If "yes," provide a basis and/or justification for your request.
			Tip: There is an option to <u>not</u> use a written consent form requiring a participant's signature prior to participation in your study. The sample informed consent form available on K-State's Research Compliance Office website outlines cases where a waiver or alteration to using a written consent form may be approved. If you request a waiver or alteration to using a written consent form, you will need to explain here why you are making this request and will have to provide a copy of your plan to provide consent elements in a different format.
Yes	☐ No	C.	Are you using the online Consent Form Template provided by the URCO? If "no," does your Informed Consent document have all the minimum required elements of informed consent found in the Consent Form Template? (Please explain)
			Tip: The sample informed consent form available on K-State's Research Compliance Office website can be modified to fit your study. If you do not plan to use this consent form template, you must describe the consent elements you will be providing to participants and how.
Yes	☐ No	D.	Are your research subjects anonymous? If they are anonymous, you will not have access to any information that will allow you to determine the identity of the research subjects in your study, or to link research data to a specific individual in any way. Anonymity is a powerful protection for potential research subjects. (An anonymous subject is one whose identity is unknown even to the researcher, or the data or information collected cannot be linked in any way to a specific person).
			Tip: If participants are not anonymous (names are tied to data), you should check no. This is typically the case for OEIE's data collections, and we say "Data will be confidential and will only pertain to gathering project stakeholders' input/feedback about the program."
Yes	☐ No	E.	Are subjects debriefed about the purposes, consequences, and benefits of the research? Debriefing refers to a mechanism for informing the research subjects of the results or conclusions, after the data is collected and analyzed, and the study is over. (If "no" explain why.) Copy of debriefing statement to be utilized should be submitted to comply@k-state.edu with your application.
			Tip: You should check yes and include a sample debriefing statement. For example, OEIE has used "Thank you for your participation in this evaluation activity. Your responses will be compiled with other individuals' responses to identify ways to improve the program. Your name will not be used in any report. If you have any questions, please contact [insert evaluation team contact information and program leadership contact information]. You may also contact the Compliance Office at Kansas State University with questions about the evaluation (comply@ksu.edu)." Like with your consent elements, your debriefing statements should be included with instrumentation submitted with your application.
		F.	Describe the Informed Consent Process:
			Who is obtaining the consent? (i.e. Principle Investigator, Graduate Student, etc.)
			Tip: Indicate who will be providing the consent form/elements and gaining participants' consent prior to their participation in the data collection. For example, who will be gaining signatures on consent forms? Who will be administering the survey or conducting the interviews/focus groups? Will another entity be assisting with gaining consent prior to the data collection (e.g., a school)?
			When and where will consent be obtained?
			Tip: Frequently participants are provided with informed consent elements immediately before participating in a data collection activity and are required to indicate consent (e.g., sign a consent form) before participating. It is possible in some situations that consent elements/forms are provided further in advance of the data collection.
			If assent (for minors) is required, please describe who will obtain the assent? (Assent means a child's affirmative agreement to participate in research)

Tip: If your research does not involve minors, enter "Not Applicable."

If	assent (for minors) is required, when and where will assent be obtain	ed?			
Tip: If your research does not involve minors, enter "Not Applicable."					
	low will consent be obtained from non-English speaking participants? rally, identify the name and qualifications of the individual providing			en	
Т	ip: If your research does not involve non-English speaking participant	s, enter "N	lot Appl	ic	
Informed Consent Checklist					
Items		YES	NO		
Does the title appear at the top of the					
Is the consent/assent form written to	toward the subject?				
Is there a statement that explains the	at the study is research?				
Is there a statement that explains the	ne purpose of the research?				
Are the procedures to be followed	explained clearly and adequately?				
Does the consent document describ research?	be risks or discomforts to subjects as a result of participating in the				
Is the consent/assent form written i	n the native language of the potential subject?			_	
Are participants compensated?				_	
maintained?	the PI, does the form detail how confidentiality of records will be				
	PI and the URCO/IRB office included?				
project without penalty or loss of b					
regardless of his or her consent?	which would require the PI to terminate a subject's participation				
biospecimens and that, after such re	be removed from the identifiable private information or identifiable emoval, the information or biospecimens could be used for future				
research studies or distributed to ar informed consent	nother investigator for future research studies without additional				
	mation or biospecimens collected as part of the research, even if used or distributed for future research studies.				
	en after identifiers are removed) may (or may not) be used for jects will or will not share in the profit.				
A statement that clinically relevant	research results will or will not be provided to subjects				
A statement indicating whether or resequencing.	not the research project will or will not include whole genome				
Is the consent document written in	lay language (Recommended 8th grade level)?				
PROJECT INFORMATION:	(If you answer Yes to any of the questions below, you should explain	n them in a	one of th	e	

IRB App	olication			Page 8
	Yes	□No	B.	Shock or other forms of punishment
Ī	Yes	☐ No	C.	Sexually explicit materials or sexual experience
Г	_ ☐ Yes	☐ No	D.	Sexual orientation
	_			
L	Yes	∐ No	E.	Sexual abuse
	Yes	☐ No	F.	Handling of money or other valuable commodities
	Yes	☐ No	G.	Extraction or use of blood, other bodily fluids, or tissues (if "yes', you must comply with facility and handling protections detailed in the 5th Edition of the Biosafety in Biomedical Laboratories (BMBL))
	Yes	☐ No	Н.	Questions about any kind of illegal or illicit activity
	Yes	No No	I.	Questions about protected health information as defined by HIPAA
	Yes	☐ No	J.	Purposeful creation of anxiety
	Yes	☐ No	K.	Any procedure that might be viewed as invasion of privacy
	Yes	☐ No	L.	Physical exercise or stress
	Yes	No No	M.	Administration of substances (food, drugs, etc.) to subjects
	Yes	No	N.	Any procedure that might place subjects at risk
	Yes	☐ No	Ο.	Will there be any use of Radioactive materials and/or use of Radioactive producing machines
L	Yes	☐ No	P.	Any form of potential abuse; i.e., psychological, physical, sexual
	Yes	☐ No	Q.	Is there potential for the data from this project to be published in a journal, presented at a conference, etc?
	Yes	☐ No	R.	Use of surveys or questionnaires for data collection. Copies should be submitted to comply@k-state.edu with your application.
	Yes	☐ No	S.	Is this a Clinical Trial? (one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.)
			MATIO	ON: (If you answer yes to any of the questions below, you should explain them in one of the
p	aragraph	s above)		
	Yes	☐ No	a.	Under 18 years of age (these subjects require parental or guardian consent)
	Yes	No No	b.	Over 65 years of age
	Yes	No No	c.	Minorities as target population
	Yes	No No	d.	Physically or mentally disabled
	Yes	No No	e.	Economically or educationally disadvantaged
	Yes	☐ No	f.	Unable to provide their own legal informed consent
	Yes	No No	g.	Pregnant females as target population
	Yes	☐ No	h.	Victims
	Yes	No No	i.	Subjects in institutions (e.g., prisons, nursing homes, halfway houses)
	Yes	No No	j.	Are subjects likely to be vulnerable to coercion or undue influence
	Yes	☐ No	k.	Is this international research? If yes, provide details as to if OHRP regulations apply in or near the area you intend to conduct research or if you have contacted individuals for applicable regulations to human subject research.
	Yes	☐ No	1.	Are research subjects in this activity students recruited from university classes or volunteer pools? If so, do you have a reasonable alternative(s) to participation as a research subject in your project, i.e., another activity such as writing or reading that would serve to protect students from unfair pressure or coercion to participate in this project? If you answered this question "Yes," explain any alternatives options for class credit for potential human subject volunteers in your study. (It is also important to remember that: Students must be free to choose not to participate in research that they

have signed up for at any time without penalty. Communication of their decision can be conveyed in

any manner, to include simply not showing up for the research.)

IKD A	pplication			Page 9
	Yes	☐ No	m.	Is audio from the subjects recorded? If yes, how do you plan to protect the recorded information and mitigate any additional risks?
				Tip: OEIE records audio, so we typically say "To accurately document participants' responses in focus groups and interviews, they will be audio taped with the permission of the participants. OEIE will store audio data on a computer network drive. The computer will remain password protected and only those involved in the evaluation project (listed as collaborators) will have access to the data." If you plan to use an external transcription service for audio files, you will need to describe that exception where a non-collaborator will have access to the data here; also specify the transcription service you plan to use and how you will maintain privacy (e.g., audio files will not be tied to participant names).
	Yes	☐ No	n.	Are research subjects' images being recorded (video taped, digitally recorded, photographed)? If yes, how do you plan to protect the recorded information and mitigate any additional risks?
XII.	FDA AC	TIVITIES	S: Answe	er the following questions about potential FDA regulated activities:
	Yes	□ No	a.	Is this a Clinical Trial?
	Yes	□ No	b.	Are you using an FDA approved drug/device/diagnostic test?
	Yes		c.	Does this activity involve the use of FDA-Regulated products? (biological products, color additives, food additives, human drugs, etc.)
	Yes	☐ No	d.	Has the protocol been submitted to the FDA, or are there plans to submit it to the FDA?
	Yes	☐ No	e.	Have you submitted an FDA form 3454 or 3455 (conflict of interest)?
XIII.	I. <u>CONFLICT OF INTEREST:</u> Concerns have been growing that financial interests in research may threaten the safety and rig of human research subjects. Financial interests are not in them selves prohibited and may well be appropriate and legitimate. Not financial interests cause Conflict of Interest (COI) or harm to human subjects. However, to the extent that financial interests may affect the welfare of human subjects in research, IRB's, institutions, and investigators must consider what actions regarding financial interests may be necessary to protect human subjects. Please answer the following questions:			
	Yes	☐ No	a.	Do you or the institution have any proprietary interest in a potential product of this research, including patents, trademarks, copyrights, or licensing agreements?
	Yes	☐ No	b.	Do you have an equity interest in the research sponsor (publicly held or a non-publicly held company)?
	Yes	☐ No	c.	Do you receive significant payments of other sorts, eg., grants, equipment, retainers for consultation and/or honoraria from the sponsor of this research?
	Yes	No No	d.	Do you receive payment per participant or incentive payments?
			e.	If you answered yes to any of the above questions, please provide adequate explanatory information so the IRB can assess any potential COI indicated above.
VIV	DDOIEC	CT COLLA	DOD 4	TOPS

X

KSU Collaborators: List anyone affiliated with KSU who is collecting or analyzing data: (list all collaborators on the project, including co-principal investigators, undergraduate and graduate students).

Enter all KSU individuals who will have access to the raw data (collection and analysis). Each person has

	Name:	Department:	Campus Phone:	Campus E-mail:				
	to complete IRB training prior to approval of the application.							
	Add Row D	elete Row						
В.	Non-KSU Collaborators : List all collaborators on your human subjects research project not affiliated with KSU in th below. KSU has negotiated an Assurance with the Office for Human Research Protections (OHRP), the federal office responsible for oversight of research involving human subjects.							
	Name:	Organization:	Phone:	Institutional E-mail:				
	individuals who will have access to the raw data (collection and analysis). Each person has to complete IRB training pri to approval of the application.							
	Add Pow	elete Pow						
		elete Row						
C.			an Assurance with OHRP? (for er Assurance Information at:					

XV. IRB Training:

A. The URCO must have a copy of the Unaffiliated Investigator Agreement on file for each non-KSU collaborator who is not covered by their own IRB and assurance with OHRP. When research involving human subjects includes collaborators who are not employees or agents of KSU the activities of those unaffiliated individuals may be covered under the KSU Assurance only in accordance with a formal, written agreement of commitment to relevant human subject protection policies and IRB oversight. The Unaffiliated Investigators Agreement can be found and downloaded at http://www.k-state.edu/research/comply/irb/forms

Online Training

TRAINING REQUIREMENTS HAVE RECENTLY CHANGED

The IRB has mandatory training requirements prior to protocol approval. Training is now offered through the Collaborative Institutional Training Initiative (CITI) Program. Instructions for registration and access to training are on the URCO website http://www.k-state.edu/research/comply/.

_Use the check boxes below to select the training courses that apply to this application. If you have any questions about training, contact URCO at comply@ksu.edu, or (785) 532-3224.

Mandatory Training					
Required for all Principal Investigators, research staff and students					
Responsible Conduct of Research					
Required (Provost-mandated) for all full-time K-State employees					
Export Compliance					
Required procedure-specific training (check all that apply to this protocol):					
☐ International Research ☐ Research in Public Elementary and Secondary Schools ☐ Research with Children					
Research with Prisoners Internet Research Vulnerable Subjects - Research Involving Workers/Employees					
Research with Subjects with Physical Disabilities and Impairments Illegal Activities or Undocument Status in Human Research					
☐ Gender and Sexuality Diversity in Human Research ☐ Research with human blood, body fluids, or tissues					
Research with Older Adults					
All new personnel or personnel with expired training are required to register for CITI and take the new					
training requirements. If you previously completed online IRB modules, your training status will remain					
current until it expires. URCO will verify training from the previous system as well as the new system prior to					
approval of any protocol.					

INVESTIGATOR ASSURANCE FOR RESEARCH INVOLVING HUMAN SUBJECTS

(Print this page separately because it requires a signature by the PI.)

P.I. Name:		
Title of Proj	ject:	
XVI. ASS	URANC	ES: As the Principal Investigator on this protocol, I provide assurances for the following:
	A.	Research Involving Human Subjects: This project will be performed in the manner described in this proposal, and in accordance with the Federalwide Assurance FWA00000865 approved for Kansas State University available at http://www.hhs.gov/ohrp/assurances/forms/filasurt.html , applicable laws, regulations, and guidelines. Any proposed deviation or modification from the procedures detailed herein must be submitted to the IRB, and be approved by the Committee for Research Involving Human Subjects (IRB) prior to implementation.
	В.	<u>Training</u> : I assure that all personnel working with human subjects described in this protocol are technically competent for the role described for them, and have completed the required IRB training accessed via the URCO website at: http://www.k-state.edu/research/comply/irb/training . I understand that no proposals will receive final IRB approval until the URCO has documentation of completion of training by all appropriate personnel.
	C.	Extramural Funding: If funded by an extramural source, I assure that this application accurately reflects all procedures involving human subjects as described in the grant/contract proposal to the funding agency. I also assure that I will notify the IRB/URCO, the KSU PreAward Services, and the funding/contract entity if there are modifications or changes made to the protocol after the initial submission to the funding agency.
	D.	Study Duration: I understand that it is the responsibility of the Committee for Research Involving Human Subjects (IRB) to perform continuing reviews of human subjects research as necessary. I also understand that as continuing reviews are conducted, it is my responsibility to provide timely and accurate review or update information when requested, to include notification of the IRB/URCO when my study is changed or completed.
	E.	Conflict of Interest: I assure that I have accurately described (in this application) any potential Conflict of Interest that my collaborators, the University, or I may have in association with this proposed research activity.
	F.	Adverse Event Reporting: I assure that I will promptly report to the IRB / URCO any <u>unanticipated</u> problems involving risks to subjects or others that involve the protocol as approved. Unanticipated or Adverse Event Form is located on the URCO website at: http://www.k-state.edu/research/comply/irb/forms . In the case of a serious event, the Unanticipated or Adverse Events Form may follow a phone call or email contact with the URCO.
	G.	Accuracy: I assure that the information herein provided to the Committee for Human Subjects Research is to the best of my knowledge complete and accurate.
You canno	ot edit the f	is form using a digital signature. DO NOT sign the form until it has been completed. Form entries once the form has been digitally signed. If you are making revisions to a previously signed form, right-click the digital signature and select signature (this can only be done by the person who originally digitally signed the form). Forms that have not been signed will not be accepted.
P.I. Sig	nature:	Date: